FY2025 Earnings Estimate for TG Therapeutics, Inc. (NASDAQ:TGTX) Issued By HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings per share estimates for shares of TG Therapeutics in a research report issued on Thursday, May 2nd. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of $0.11 per share for the year, down from their prior estimate of $0.19. HC Wainwright currently has a "Buy" rating and a $49.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for TG Therapeutics' FY2026 earnings at $0.49 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The firm had revenue of $63.47 million during the quarter, compared to analysts' expectations of $54.60 million. TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The business's revenue for the quarter was up 713.5% on a year-over-year basis. During the same period last year, the company earned ($0.28) earnings per share.

Several other analysts also recently issued reports on the company. B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Monday, February 5th. StockNews.com cut shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, February 29th. LADENBURG THALM/SH SH increased their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. reaffirmed an "overweight" rating and issued a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $29.83.

TG Therapeutics Price Performance

TGTX stock traded up $0.32 during trading on Monday, reaching $16.51. The company's stock had a trading volume of 3,777,326 shares, compared to its average volume of 4,334,321. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The company's fifty day moving average is $15.25 and its 200-day moving average is $14.52. The company has a market capitalization of $2.55 billion, a P/E ratio of 70.39 and a beta of 2.33. TG Therapeutics has a 1 year low of $6.46 and a 1 year high of $35.22.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its stake in shares of TG Therapeutics by 3.9% during the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock valued at $538,000 after purchasing an additional 1,322 shares in the last quarter. Wealth Effects LLC boosted its position in TG Therapeutics by 17.9% during the 1st quarter. Wealth Effects LLC now owns 16,500 shares of the biopharmaceutical company's stock valued at $251,000 after acquiring an additional 2,500 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of TG Therapeutics by 4.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 107,420 shares of the biopharmaceutical company's stock valued at $1,634,000 after acquiring an additional 4,548 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of TG Therapeutics by 16.9% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company's stock worth $2,811,000 after acquiring an additional 26,761 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of TG Therapeutics by 55.8% in the 1st quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company's stock worth $1,165,000 after acquiring an additional 27,437 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares of the company's stock, valued at approximately $3,437,207.13. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 9.20% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.